EMAIL DIGESTS
Daily
Every morning
Weekly
Sunday recap
LLY
Lilly is a medicine company turning science into healing to make life better for people around the world.
Baseline Debuts To Challenge GLP-1 Giant Lilly in Alcohol Use Disorder
5 FDA Decisions to Watch in the First Quarter of 2026
Keep an Eye on These 15 Biotech Companies in 2026
AbbVie, Amgen, Lilly Lead Calls for FDA To Update Post-Approval Change Rules
Novartis Breaks Ground on San Diego Biomedical R&D Site
Biotech in 2025: A Retrospective
Lilly Bulks Up Inflammatory Pipeline With $1.2B Ventyx Buy, InduPro Cancer Pact
Pfizer’s Early Metsera Data Leaves Analysts Wanting More
Breast Cancer Treatments Heat Up: Six Therapies Poised to Transform Patient Outcomes
Lilly’s GLP-1s Mounjaro, Zepbound Push Revenue up 46% in Q4
FDA Sets Feb. 1 Launch Date for PreCheck Pilot To Strengthen Domestic Supply Chain
Syremis Therapeutics Raises $165M in Series A Financing
Deals Not Waiting for JPM
How Eli Lilly’s Biotech Collaboration Model Is Rewriting Early-Stage Innovation
JPM26: Protagonist Has a $400M Decision To Make. It’s a No-Brainer
3 Trends Shaping the GLP-1 Landscape
Lilly Establishes up to $2.7B Repertoire Deal in Second Immune Play of 2026
Roche Raises NC Manufacturing Investment to $2B To Support Obesity Challenge
Sanegene Bio Closes Over $110 Million Series B
What We Still Don’t Know About Weight-Loss Drugs
A New Approach to Drugging MYC: The Application of Translation-Inhibiting Interdictors To MYC-Driven Malignancies
Advanced Therapies Week 2026: ‘Solving for Science’ and Weathering Global Complexity
Novo Combination Obesity Shot Meets Goal in Diabetes Trial
Novo Launches Oral Obesity Pill, Lilly Targets Lofty Revenue, FDA and M&A in Focus
GLP-1 Drugs Linked to Pancreatitis, Gallbladder Problems
The Benefits of an Immune-Directed ADC Strategy
Politicization Runs Deeper than Ever at FDA, Risking Long-Term Impacts
The Top 10 PharmTech Videos of 2025
Why Owning the Learning Loop Matters More Than Owning the Lab
Overlooked and Undervalued: Why Novo Nordisk Stock Deserves Attention
New Lilly Data Suggest Zepbound Boosted Effect of Autoimmune Drug
Blocking the IgG Highway: FcRn Biology, Approved Agents, and the Small Molecule Horizon
Proteasomes: A Novel Approach to Target the Immune System
JPM26 Recap, Novo’s Oral Wegovy Soars as Lilly’s Orforglipron Is Delayed, IPOs Return
CMS's Medicare Price Negotiations Start Round Three
Obesity Data, Kymera and FDA Sentiment Survey Results — a BioCentury Podcast
Ex-CEO Behind Bars, 10x’s Clinical Ambitions, Pharma’s AI Gambit
Women Leading Biotech: Advancing Treatments for Ovarian Cancer
Aktis Lands Biotech's First IPO of 2026, Raising $318M for Radiopharmaceuticals
Nine Biotech Companies that Could Revolutionize Obesity Treatments
FDA Delays Decision for Lilly’s Obesity Pill Orforglipron, Other Priority Voucher Awardees: Report
Report Says MSD Is in Talks to Buy Revolution Meds
#JPM26: Regeneron, Lilly, Summit on Rivals Crowding Into Same Targets
Biotech’s Next Chapter: Asset-Centric Deals and Shifting Alpha at JPM 2026
Lilly’s Triple Agonist Contender for Best-in-Class Weight Loss
Lilly Doubles Down With Nimbus, Paying $55M for Preclinical Obesity Drug
Lilly Strikes Again, Buying CAR-T Firm Orna for $2.4bn
Facing Talent Crunch, Radiopharma Field Casts a Wide Net
AZ Signals All-In on Obesity via CSPC Deal for $1.2B up Front
Fed Rate Cut Tailwind, Lilly’s Triple Agonist Delivers Big, Vaccine Policy Turmoil — This Week in Biotech #81
Eli Lilly to Acquire Ventyx Biosciences for $1.2B
Gate Bioscience Secures $65M Series B Round Led by Forbion and Eli Lilly
Eli Lilly Pays $100M for Rights to CSL’s Clazakizumab
Sanegene Bio Secures Over $110M in Series B Funding
Excelsior Sciences Secures $95M Series A Funding Led by Deerfield, Khosla and Sofinnova
Eli Lilly to Acquire Ventyx for $1.2B
Eli Lilly and Nvidia Sign Five‑year, up to $1 Billion AI Laboratory Deal
Eli Lilly to Acquire Orna Therapeutics for $2.4 Billion